0001213900-24-012839.txt : 20240212 0001213900-24-012839.hdr.sgml : 20240212 20240212214226 ACCESSION NUMBER: 0001213900-24-012839 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240212 DATE AS OF CHANGE: 20240212 GROUP MEMBERS: PVBQ LIVING TRUST SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Cadrenal Therapeutics, Inc. CENTRAL INDEX KEY: 0001937993 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 880860746 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-94027 FILM NUMBER: 24622354 BUSINESS ADDRESS: STREET 1: 822 A1A NORTH STREET 2: SUITE 300 CITY: PONTE VEDRA STATE: FL ZIP: 32082 BUSINESS PHONE: 904-300-0701 MAIL ADDRESS: STREET 1: 822 A1A NORTH STREET 2: SUITE 300 CITY: PONTE VEDRA STATE: FL ZIP: 32082 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Pham Quang X CENTRAL INDEX KEY: 0001405290 ORGANIZATION NAME: FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: 89 MELROSE DRIVE CITY: MISSION VIEJO STATE: CA ZIP: 92692 SC 13G 1 ea193366-13gpham_cadrenal.htm SCHEDULE 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.     )*

 

Cadrenal Therapeutics, Inc.

(Name of Issuer)

 

Common Stock, $0.001 par value per share

(Title of Class of Securities)

 

127636 108

(CUSIP Number)

 

Quang Pham

c/o Cadrenal Therapeutics, Inc.

822 A1A North, Suite 306

Ponte Vedra, Florida 32082

(904) 300-0701

(Name, address and telephone number of person authorized to receive notices and communications)

 

With a copy to:

 

Leslie Marlow, Esq.

Blank Rome LLP

1271 Avenue of the Americas

New York, New York 10020

(212) 885-5000

 

December 31, 2023

(Date of event which requires filing of this statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

  

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

  

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 127636 108 SCHEDULE 13G Page 2 of 7 Pages

 

1 NAME OF REPORTING PERSON
     
  Quang X. Pham
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
      Not applicable (b) ☐
3 SEC USE ONLY  
     
4 CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States of America

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH  
5 SOLE VOTING POWER
   
  3,325,000 (1) shares
6 SHARED VOTING POWER
   
  3,000,000
7 SOLE DISPOSITIVE POWER
   
  3,325,000 (1) shares
8 SHARED DISPOSITIVE POWER
   
  3,000,000

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
  6,325,000 shares (1)
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ☐
     
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
     
  48.57 % (2)  
12 TYPE OF REPORTING PERSON  
     
  IN  

 

(1)Does not include 150,000 shares of common stock issuable upon the exercise of options held by Mr. Pham that are not exercisable within 60 days hereof.

 

(2)This percentage is calculated based on 13,022,754 shares of Common Stock of the Issuer issued and outstanding as of December 31, 2023.

 

 

 

 

CUSIP No. 127636 108 SCHEDULE 13G Page 3 of 7 Pages

 

1 NAME OF REPORTING PERSON
     
  The PVBQ Living Trust
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
      Not applicable (b) ☐
3 SEC USE ONLY  
     
4 CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Florida

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH  
5 SOLE VOTING POWER
   
  0 shares
6 SHARED VOTING POWER
   
  3,000,000
7 SOLE DISPOSITIVE POWER
   
  0 shares
8 SHARED DISPOSITIVE POWER
   
  3,000,000

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
  3,000,000 shares
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ☐
     
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
     
  23.04 % (1)  
12 TYPE OF REPORTING PERSON  
     
  OO (Trust)  

 

(2)This percentage is calculated based on 13,022,754 shares of Common Stock of the Issuer issued and outstanding as of December 31, 2023.

 

 

 

 

CUSIP No. 127636 108 SCHEDULE 13G Page 4 of 7 Pages

 

Item 1(a)

Name of Issuer:

 

Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”)

   
Item 1(b)

Address of Issuer’s Principal Executive Offices:

 

822 A1A North, Suite 306

Ponte Vedra, Florida 32082

   
Item 2(a)

Name of Person Filing:

 

Quang Pham (sometimes referred to as the “Reporting Person”) and The PVBQ Living Trust (sometimes referred to as the “Trust”). The beneficiary of the Trust is Mr. Pham’s child and Mr. Pham is the trustee of the Trust, with has sole voting and disposition power with respect to the shares owned by the Trust.

   
Item 2(b)

Address of Principal Business Office or, if none, Residence:

 

The address for the principal business office of the Reporting Person and the Trust is:

 

c/o Cadrenal Therapeutics, Inc.

822 A1A North, Suite 306

Ponte Vedra, Florida 32082

   
Item 2(c)

Citizenship:

 

The Reporting Person is a citizen of the United States. The Trust was formed under the laws of the State of Florida.

   
Item 2(d)

Title of Class of Securities:

 

Common Stock, par value $0.001 per share (“Common Stock”)

   
Item 2(e)

CUSIP No.:

 

127636 108

  

Item 3.

If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the Person Filing is:

 

Not applicable

  

  (a) Broker or dealer registered under Section 15 of the Exchange Act;
       
  (b) Bank as defined in Section 3(a) (6) of the Exchange Act;
       
  (c) Insurance company as defined in Section 3(a) (19) of the Exchange Act;
       
  (d) Investment company registered under Section 8 of the Investment Company Act;
       
  (e) An investment adviser in accordance with Rule 13d-1(b) (1) (ii) (E);
       
  (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b) (1) (ii) (F);
       
  (g) A parent holding company or control person in accordance with Rule 13d-1(b) (1) (ii) (G);
       
  (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
       
  (i) A church plan that is excluded from the definition of an investment company under Section 3(c) (14) of the Investment Company Act;
       
  (j) Group, in accordance with Rule 13d-1(b) (1) (ii) (J).

  

 

 

 

CUSIP No. 127636 108 SCHEDULE 13G Page 5 of 7 Pages

 

Item 4. Ownership

 

As of the close of business on December 31, 2023, the Reporting Person held an aggregate of 6,325,000 shares of Common Stock, which shares include (i) 3,325,000 shares of Common Stock owned by Quang Pham directly; and (ii) 3,000,000 shares of Common Stock owned by The PVBQ Living Trust. The beneficiary of the Trust is Mr. Pham’s child and Mr. Pham is the trustee of the Trust and has sole voting and disposition power with respect to the shares owned by the Trust. The Reporting Person also was issued an option to purchase 150,000 shares of Common Stock on January 18, 2024, of which 0 shares have vested and are exercisable within 60 days of the date of this Report, and which shares are not included in the total shares beneficially owned by the Reporting Person as of December 31, 2023.

 

The following sets forth in tabular format the share ownership of the Reporting Person as of December 31, 2023:

 

(a)Amount beneficially owned:   6,325,000 shares of Common Stock

 

(b)Percent of class:  48.57 %

 

(c)Number of shares as to which such person has:

 

  (i) sole power to vote or to direct the vote: 3,325,000 shares
     
  (ii) shared power to vote or to direct the vote: 3,000,000 shares
     
  (iii) sole power to dispose or to direct the disposition of: 3,325,000 shares
     
  (iv) shared power to dispose or to direct the disposition of: 3,000,000 shares

 

The following sets forth in tabular format the share ownership of the Trust as of December 31, 2023:

 

  (a) Amount beneficially owned:   3,000,000 shares of Common Stock

 

  (b) Percent of class:  23.04 %

 

  (c) Number of shares as to which such person has:

 

  (i) sole power to vote or to direct the vote: 0 shares
     
  (ii) shared power to vote or to direct the vote: 3,000,000 shares
     
  (iii) sole power to dispose or to direct the disposition of: 0 shares
     
  (iv) shared power to dispose or to direct the disposition of: 3,000,000 shares

 

 

 

 

CUSIP No. 127636 108 SCHEDULE 13G Page 6 of 7 Pages

 

Item 5. Ownership of Five Percent or Less of a Class.
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
   
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
   
  As discussed in Item 4, certain shares of Common Stock that the Reporting Person may be deemed to own beneficially are held by or on behalf of persons other than the Reporting Person, which other persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities.
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
   
  Not applicable.
   
Item 8. Identification and Classification of Members of the Group.
   
  Not applicable.
   
Item 9. Notice of Dissolution of Group.
   
  Not applicable.
   
Item 10. Certifications.
   
  Not applicable.

  

[signature page follows]

 

 

 

 

CUSIP No. 127636 108 SCHEDULE 13G Page 7 of 7 Pages

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

  

Date: February 12, 2024

 

  /s/ Quang Pham
  Quang Pham

 

  THE PVBQ LIVING TRUST
     
  By: /s/ Quang Pham
    Quang Pham
    Trustee

 

 

 

EX-99.1 2 ea193366ex99-1_cadrenal.htm JOINT FILING AGREEMENT

Exhibit 1

 

JOINT FILING AGREEMENT

 

JOINT FILING AGREEMENT, dated as of February 12, 2024, among Quang Pham and The PVBQ Living Trust (collectively, the “Reporting Persons”).

 

WHEREAS, pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the parties hereto desire to satisfy any filing obligation under Section 13(d) of the Exchange Act by a single joint filing;

 

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Reporting Persons hereby agree and represent as follows:

 

1.Schedule 13G with respect to the Common Stock, par value $0.001 per share, of Cadrenal Therapeutics, Inc. (to which this Joint Filing Agreement is an exhibit) is filed on behalf of each of the Reporting Persons.

 

  2. Each of the Reporting Persons is responsible for the timely filing of Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such Person contained therein, provided that each such Person is not responsible for the completeness or accuracy of the information concerning any of the other Reporting Persons, unless such Person knows or has reason to believe that such information is inaccurate.

 

IN WITNESS WHEREOF, the undersigned have caused this Joint Filing Agreement to be duly executed and delivered as of the date first above written.

 
  /s/ Quang Pham
  Quang Pham

 

  THE PVBQ LIVING TRUST
     
  By: /s/ Quang Pham
    Quang Pham
    Trustee